Exenatide

艾塞那肽

Report date: 2026/05/05 20:00:16
NMEFirst In Class

Base Information

Drug NameExenatide
Drug Alias NameExenatida依泽那太Exenatide LAR依克那肽Exenatidum +[18
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsHypothalamic ObesityIschemic StrokeCognitive Dysfunction +[35
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryUnited States
Original Approved Date2005/04/28
Country/TerritoryCzechiaBelgiumBulgaria +[51
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
China Registration ClassN/A

Develop Information

Active IndicationsCocaine-Related DisordersPediatric ObesityObesity +[9
Inactive IndicationsHypothalamic ObesityIschemic StrokeCognitive Dysfunction +[26

Other Information

ATC CodeA10BJ01